We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 936

Teva’s Skinny Label Found Not to Induce Infringement by Off-Label Use
  • McDermott Will & Emery
  • USA
  • July 18 2018

The US District Court for the District of Delaware granted in part Teva Pharmaceuticals' renewed motion for judgment as a matter of law (JMOL


When is There Standing to Appeal a PGR Final Written Decision?
  • Marshall Gerstein & Borun LLP
  • USA
  • July 5 2018

In Altaire Pharm., Inc. v. Paragon Biotek, Inc., Case No. 2017-1487 (Fed. Cir. May 2, 2018), the Federal Circuit reversed in part a PGR final written


A Petitioner’s Dilemma in Post-Grant Reviews
  • K&L Gates
  • USA
  • June 5 2018

Post-grant reviews ("PGRs") can only be filed within a nine-month window starting from the issuance of the patent, but standing to appeal to the


ITC Institutes Investigation Based on Allegation of Drug Sales Without FDA Approval
  • Jones Day
  • USA
  • May 17 2018

Normally, it is the FDA that monitors the improper distribution of drugs. But, as it turns out, the International Trade Commission ("ITC") might be


Jurisdiction for “Late Listed” Orange Book Patent and Injunction Based on Induced Infringement by Drug Label
  • Oblon
  • USA
  • April 25 2018

As reported earlier, the Federal Circuit in Vanda Pharm. Inc. v. West-Ward Pharm. Int’l. Ltd. held that jurisdiction exists under 35 U.S.C


Judge Stark (D. Del.) Holds Generic Label is Insufficient to Prove Induced Infringement
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • April 9 2018

Following a seven-day trial last year, a jury found that Teva willfully induced infringement of claims of U.S. Patent


No State Law Remedies for Failure to Comply with BPCIA Notice
  • McDermott Will & Emery
  • USA
  • January 25 2018

On remand from the Supreme Court of the United States, the US Court of Appeals for the Federal Circuit held that under the Biologics Price


Does It Still Cost $2.7B to Develop a Drug? Regardless, Patent Protection is Key!
  • Dilworth IP
  • USA
  • January 23 2018

We have previously reported that the cost to develop a new drug is roughly $2.7B (inflation adjusted). This price tag was determined by the Tufts


Sandoz v Amgen: An update
  • Bristows
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest


Anticipated Acts of Infringement May Establish Venue for Hatch-Waxman
  • McDermott Will & Emery
  • USA
  • October 31 2017

Addressing venue in the context of Hatch-Waxman litigation, the US District Court for the District of Delaware held that venue is proper in Delaware